Bluejay Diagnostics completes 624 of 750 patient enrollments in SYMON-II sepsis trial

Bluejay Diagnostics, Inc.

SYMON-II pivotal trial for Symphony IL-6 sepsis triage test enrolled 624 of 750 target patients.
Enrollment completion expected within 2-3 months, subject to site activity and patient flow.
Inclusion and exclusion criteria have not caused significant patient exclusions, per CEO Neil Dey.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.